An unique treatment for an unusual type of kidney cancer has actually been revealed.
There are presently no tested treatments for metastatic or irresectable chromophobe kidney cell cancer (ChRCC), an unusual kind of kidney cancer.
Researchers offer the very first proof that ChRCC can be treated with ferroptosis in a research study headed by Brigham and Women’s Hospital scientists. Ferroptosis is a sort of set cell death that takes place when extreme amounts of iron cause lipid peroxides to develop in the cell membrane.
By denying ChRCC cells of cysteine, the group had the ability to cause ferroptosis, and they found proof that this method would work in the treatment of ChRCC.
“Targeted therapies are urgently needed to treat chromophobe RCC,” stated matching author Elizabeth P. Henske, MD, of the Division of Pulmonary and Critical Care Medicine at Brigham.
“Through our study, we’ve found strong evidence that ChRCC can be therapeutically targeted by taking advantage of the cells’ hypersensitivity to ferroptosis. This represents an important breakthrough in our understanding as we think about treatment for patients with this rare disease.”
Reference: “Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11” by Long Zhang, Charbel S. Hobeika, Damir Khabibullin, Deyang Yu, Harilaos Filippakis, Michel Alchoueiry, Yan Tang, Hilaire C. Lam, Peter Tsvetkov, George Georgiou, Candice Lamb, Everett Stone, Pere Puigserver, Carmen Priolo and Elizabeth P. Henske, 8 July 2022, Proceedings of the National Academy of Sciences.
The research study was moneyed by the NIH/National Institutes of Health, the Tuttle Family, the van Hecke Family, the Christelis Family, and the Cohen/LevinFamily